LifeMD Inc (LFMD) Q4 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Investments Propel Future Prospects

Eli Lilly is investing $5bn in a new production site in Virginia, part of a $50bn plan to expand US drug manufacturing. The facility will be the company's first fully integrated plant, producing both APIs and finished drugs. It is the tenth new US site since 2020.

Evaxion A/S reported 3-year phase 2 data for EVX-01 in advanced melanoma, showing 89% target precision, immune responses in all patients, and no tumor progression in monotherapy patients. The data will be presented at ESMO 2026. According to the company, the results support its AI-Immunology platform and EVX-01's potential efficacy.

Evaxion A/S (NASDAQ: EVAX) reported three-year data from its phase 2 trial of EVX-01, a personalized cancer vaccine for advanced melanoma. All six patients in the trial's extension showed no tumor progression, maintaining responses seen at two years. The data will be presented at ESMO 2026. EVX-01 induced an immune response in all patients, with 89% of vaccine neoantigens generating potent T-cell responses.

SK hynix has postponed Solidigm's $150 billion US IPO due to semiconductor stock corrections and regulatory scrutiny. Solidigm, a NAND flash subsidiary, reported first-half revenue of 12.25 trillion won ($9.2 billion) and net income of 5.84 trillion won. The decision allows SK hynix to reassess financing options while retaining flexibility for future investments.

CBRE reports 80% of North American data center capacity under construction is pre-leased, up from 74% a year earlier. Bitdeer (BTDR) secured $2.9B in AI cloud revenue backlog, with commitments for facilities in Malaysia and Norway. The company follows a strategy of contracting demand before developing capacity, with long-term leases and prepayments.

SeaStar Medical (ICU) reported higher survival rates in pediatric kidney injury patients treated with QUELIMMUNE. The analysis compared 43 treated patients to 196 historical cases, showing 65.1% survival at day 90 vs. 47.4%. No device-related adverse events were reported. ICU shares closed at $2.85, up 3.51% after-hours.